You are here: Industry Insights > OWP

News List

OWP Pharmaceuticals Announces Patent Application for Treatment of Attention Deficit Hyperactivity Disorder americanpharmaceuticalreview
April 23, 2021
OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations.
OWP Announces IND Approval for Quetiapine Fumarate Liquid Oral Suspension Formulation americanpharmaceuticalreview
October 10, 2020
OWP has received approval for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for the first-ever liquid formulation of quetiapine fumarate.
OWP Announces Patent Application for Duloxetine Hydrochloride Powder for Depression, Anxiety americanpharmaceuticalreview
July 20, 2020
OWP Pharmaceuticals has submitted for U.S. patent protection for the first powder for oral liquid formulation of duloxetine hydrochloride.
OWP Announces Pre-IND Acknowledgement, Patent Application for Schizophrenia, Bipolar Disorder Treatment americanpharmaceuticalreview
January 13, 2020
OWP Pharmaceuticals has received Pre-Investigational New Drug (PIND) acknowledgement from the U.S. Food and Drug Administration (FDA), and has submitted for U.S. patent protection, for the first-ever liquid formulation of quetiapine fumarate.
OWP Announces Second IND Approval for Lamotrigine Liquid Oral Suspension Formulation americanpharmaceuticalreview
December 30, 2019
OWP Pharmaceuticals has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), and has submitted for U.S. patent protection ...